The board of directors of Luye Pharma Group Ltd. announced that, according to Shandong Boan Biological Technology Co. Ltd., the clinical trial application of the biological antibody LY09004 has been accepted by National Medicine Product Administration in China. In addition to LY09004, the Group has three antibody products under different stages of clinical trial, including recombinant anti-VEGF humanised monoclonal antibody injection biosimilar (LY01008), which has entered phase III clinical trial, and Recombinant anti-RANKL fully human monoclonal antibody injection biosilimar (LY06006 and LY01011), which have entered phase I clinical trial. The Group will continue to invest in R&D in the field of biopharmaceuticals, to accelerate the deployment of the Group's innovative bio-pharmaceuticals, and further enrich the Group's product pipeline in thefield of oncology, among others.